retatrutide case study Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Inotropic effects of retatrutide in

Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes

Janoshik testing information

Gastric Emptying Modulation GLP2 transiently delays gastric emptying, similar to selective GLP-1 receptor agonists: Slowed rate of nutrient absorption from the gastrointestinal tract Reduced postprandial glucose excursions Effect is most pronounced after initial doses and diminishes with continued treatment Contributes to improved glycemic control through multiple complementary mechanisms Central Nervous System Effects Appetite Regulation Both GIP and GLP-1 receptors are expressed in brain regions controlling appetite and food intake: Reduced food intake and appetite through central nervous system receptor activation Promotion of satiety signals leading to decreased caloric consumption Potential modulation of reward-related feeding behaviors Weight loss effects that appear mediated through both homeostatic and hedonic feeding pathways Clinical trials have demonstrated substantial weight reduction, with participants experiencing decreased appetite as a commonly reported effect of GLP2 treatment

A separate weight-management indication is subject to ongoing MHRA and NICE appraisal processes as of the time of writing

Thomas, L

doi: 10.1016/j.nutres.2020.04.001 26 iftciG.TunaE